title: Human PTH(1-34) infusion test in differential diagnosis of various types of hypoparathyroidism: an attempt to establish a standard clinical test.
abstract: To introduce a simple procedure and reliable diagnostic criteria for parathyroid hormone (PTH) infusion test, 128 patients with either pseudo- (PsH) or idiopathic hypoparathyroidism (IdH) and 25 normocalcemic controls were studied. Incremental responses of urinary cyclic AMP and phosphate to 20 micrograms (67 U) or 30 micrograms (100 U) of human PTH(1-34) were assessed by using simple parameters of urinary excretion rates of the two substances. The results are summarized as follows. (1) PTH dose-cyclic AMP response relation suggests that 100 U of PTH is more appropriate than 67 U as a standard test dose for adults. (2) By presenting the magnitude of cyclic AMP response as either net increase or fold increase during 1 h after 100 U of PTH infusion, we can differentiate PsH type I from others without overlap. (3) Differentiation between PsH and IdH or normocalcemic subjects by phosphaturic response is less clearcut than that made by cyclic AMP response whatever indices and criteria are used. Thus it seems difficult to diagnose PsH type II merely based on the discrepancy between cyclic AMP and phosphaturic responses to exogenous PTH. (4) The test results are essentially similar in the examinations performed before and during vitamin D therapy. However, when the magnitude of phosphaturic response is expressed as net increase during 2 h after PTH, it tends to be enhanced after vitamin D therapy in patients with PsH compared to the response before therapy.
authors.affiliation: Fourth Department of Internal Medicine, University of Tokyo School of Medicine, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Yamamoto
authors.forename: Y
authors.initials: Y
authors.lastname: Furukawa
authors.forename: Y
authors.initials: Y
authors.lastname: Konagaya
authors.forename: H E
authors.initials: HE
authors.lastname: Sohn
authors.forename: A
authors.initials: A
authors.lastname: Tomita
authors.forename: T
authors.initials: T
authors.lastname: Fujita
authors.forename: E
authors.initials: E
authors.lastname: Ogata
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002118:Calcium / Q000097:blood; D002648:Child; D002940:Circadian Rhythm; D002985:Clinical Protocols / Q000592:standards*; D003401:Creatine / Q000097:blood / Q000652:urine; D000242:Cyclic AMP / Q000097:blood / Q000652:urine; D003937:Diagnosis, Differential; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D007037:Hypothyroidism / Q000145:classification / Q000175:diagnosis*; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000008:administration & dosage / Q000494:pharmacology; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology; D010710:Phosphates / Q000097:blood / Q000652:urine; D012015:Reference Standards; D019379:Teriparatide
chemical_list: D010281:Parathyroid Hormone; D010446:Peptide Fragments; D010710:Phosphates; D019379:Teriparatide; D000242:Cyclic AMP; D003401:Creatine; D002118:Calcium